SCHEMBL2762701

SCHEMBL2762701

O=S(=O)(Nc1nc2c(s1)CCc1sccc1-2)c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.39
SLC40A1 Q9NP59 1/20 0.38
MAPT P10636 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TP53 P04637 2/20 0.37
USP2 O75604 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
POLB P06746 2/20 0.37
ACLY P53396 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
RECQL P46063 1/20 0.37
ESR2 Q92731 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762651 0.92 PFKFB3 (0.38) HSD11B1MAPTSMN1; SMN2TP53USP2
SCHEMBL2763048 0.83 CCR2 (0.43) SMN1; SMN2PKMKDM1ALMNAHTT
SCHEMBL2762411 0.80 MAPT (0.62) MAPTSMN1; SMN2TP53NPSR1CYP1A2
SCHEMBL2762497 0.78 MAPT (0.46) MAPTSMN1; SMN2TP53NPSR1CYP1A2
SCHEMBL2762715 0.78 LMNA (0.45) MAPTSMN1; SMN2USP2NPSR1POLB
SCHEMBL2762604 0.78 HSD11B1 (0.47) HSD11B1SLC40A1HTT
SCHEMBL2762753 0.75 MAPT (0.58) MAPTSMN1; SMN2TP53NPSR1CYP1A2
SCHEMBL2763044 0.74 MEN1 (0.47) HSD11B1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL2763675 0.72 AKT1 (0.45) SMN1; SMN2HSD17B10PKMLMNAHTT
SCHEMBL2762452 0.70 PFKFB3 (0.34) HSD11B1MAPTPKMKDM1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP claimed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885SLC40A1 2471/4885MAPT 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.